FDA News

FDA clears NUCRYST Pharmaceuticals' Antimicrobial Barrier Topical Cream

(July 19, 2007)-- NUCRYST Pharmaceuticals announced that the US Food & Drug Administration (FDA) has granted 510(k) clearance for a prescription topical cream containing NPI 32101, the company's patent-protected nanocrystalline silver, as a broad-spectrum antimicrobial barrier.

"NPI 32101 cream represents a new presentation of our patented nanocrystalline silver technology," said Scott H. Gillis, President & CEO, NUCRYST Pharmaceuticals Corp. "Gaining FDA clearance is a first step toward
marketing our proprietary technology in this new formulation. We are actively exploring commercialization options and as part of this process, market plans and timing for this product will be determined."

In vitro studies have demonstrated that NPI 32101 cream serves as a broad-spectrum antimicrobial barrier to organisms including Pseudomonas aeruginosa and Staphylococcus aureus, including strains resistant to
Methicillin (MRSA). Clinical studies involving more than 600 adults and children have also demonstrated that it has a strong safety profile.

Share or bookmarklet this web page at: